These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3273615)

  • 1. Reports on cases of neurological illnesses occurring after administration of acellular pertussis vaccines in Japan.
    Kimura M; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():165-70. PubMed ID: 3273615
    [No Abstract]   [Full Text] [Related]  

  • 2. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe neurological illness: further analyses of the British National Childhood Encephalopathy Study.
    Miller D; Wadsworth J; Ross E
    Tokai J Exp Clin Med; 1988; 13 Suppl():145-55. PubMed ID: 3273614
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neurologic manifestations following pertussis vaccination].
    Aicardi J; Chevrie JJ
    Arch Fr Pediatr; 1975 Apr; 32(4):309-17. PubMed ID: 240337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of pertussis immunization to the onset of epilepsy, febrile convulsions and central nervous system infections: a retrospective epidemiologic study.
    Jacobson V; Nielsen C; Buch D; Shields WD; Christenson P; Zachau-Christiansen B; Cherry JD
    Tokai J Exp Clin Med; 1988; 13 Suppl():137-42. PubMed ID: 3273613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic manifestations in children with influenza B virus infection.
    Lin CH; Huang YC; Chiu CH; Huang CG; Tsao KC; Lin TY
    Pediatr Infect Dis J; 2006 Nov; 25(11):1081-3. PubMed ID: 17072138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of currently available Japanese acellular pertussis vaccines and future problems.
    Kamiya H; Nii R
    Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Kuno-Sakai H; Kimura M; Watanabe H
    Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis.
    Kimura M; Kuno-Sakai H
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):263-73. PubMed ID: 3508651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following immunization with DTP vaccine.
    Stetler HC; Mullen JR; Brennan JP; Orenstein WA; Bart KJ; Hinman AR
    Dev Biol Stand; 1985; 61():411-21. PubMed ID: 3879686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis immunisation and serious acute neurological illnesses in children.
    Miller D; Madge N; Diamond J; Wadsworth J; Ross E
    BMJ; 1993 Nov; 307(6913):1171-6. PubMed ID: 7504540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pertussis vaccine.
    Nong AT; Werblun MN
    Am Fam Physician; 1983 Feb; 27(2):127-8. PubMed ID: 6829367
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka.
    Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K
    Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of recurrence after a first unprovoked seizure.
    Berg AT
    Epilepsia; 2008; 49 Suppl 1():13-8. PubMed ID: 18184149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Whooping cough vaccination in children with neurological disorders].
    Barth PG
    Ned Tijdschr Geneeskd; 1984 Jul; 128(30):1423-4. PubMed ID: 6472506
    [No Abstract]   [Full Text] [Related]  

  • 20. Pertussis immunization; family history of convulsions and use of antipyretics--supplementary ACIP statement.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 May; 36(18):281-2. PubMed ID: 3155353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.